Genialis expands its collaboration with Debiopharm, deploying Expressions to support standardized biomarker discovery and ...
While the use of precision therapies continues to expand, precision oncology drug development is facing increasing costs and complexity. In today's biomarker-driven landscape, it is more important ...
Cancer biomarkers span a broad biological spectrum, including proteins, metabolites, and nucleic acids detectable in samples such as tissue biopsies and blood. 1 At the beginning of a biomarker ...
GENT, Belgium & FREMONT, Calif.--(BUSINESS WIRE)--ADx NeuroSciences, a wholly owned subsidiary of Fujirebio and a leader in neurodegenerative disease biomarker development, and Alamar Biosciences, a ...
Extending their collaboration, Genialis and Debiopharm continue working towards a patient classifier to support WEE1 clinical development BOSTON--(BUSINESS WIRE)-- Genialis, the RNA biomarker company, ...
Extracellular vesicles (EVs), including exosomes, microvesicles, apoptotic bodies, and many other EV subtypes, have emerged ...
Background: The Prognostic Lung Fibrosis Consortium (PROLIFIC) was formed to develop well-qualified assays suitable for use as prognostic biomarkers within the context of clinical trials for Idiopathic ...
Biomarkers (a shortened term for biological markers) are measurable characteristics of a certain biological condition or response to a medical or environmental exposure. Some biomarkers, such as blood ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback